Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.
Therapy Areas in Europe
Good health and wellbeing is a universal aspiration, and we continue to seek ways to help patients in achieving better health and a better quality of life. In Europe our pharmaceutical business employs over 550 people, all of whom channel their energy into exploring solutions that we hope will make a difference to patients’ lives. We aim to help people with diseases that range from those affecting millions to those that affect relatively few.
The health and wellbeing of patients is our primary focus, and we put the needs and views of patients, carers and healthcare professionals at the heart of the work we do.
We aim to help patients in the following therapy areas: neuroscience, nephrology, haemato-oncology and endocrinology.
Otsuka’s commitment to providing innovative solutions for mental health disorders began over 30 years ago when our researchers undertook the first steps with an aim to help millions of people affected by schizophrenia and bipolar disorder.
Otsuka has a long-term alliance with Lundbeck, a company that also has extensive experience in mental health disorders
With our partner Astex, we are currently focusing on haematological malignancies, such as acute myeloid leukaemia.
Nephrology is a therapy area with a large unmet medical need. We work with patients and healthcare professionals to increase awareness of kidney diseases, including autosomal dominant polycystic kidney disease, an inherited disorder that can impair kidney function and lead to kidney failure requiring dialysis and potentially eventual kidney transplant. We are also working with our partner Akebia, exploring chronic kidney disease, including associated anaemia.
For decades, Otsuka has been conducting research in endocrinology (the medical specialty concerned with hormones) to understand how hormone-related conditions could be affected.
One such condition that Otsuka has focused on is hyponatraemia, which causes abnormally low levels of sodium in the blood.
Date of preparation: October 2020
This website is for all those with an interest in Otsuka Pharmaceutical Europe Ltd.